Works matching AU Peytavin, Gilles

Results: 135
    1
    2
    3
    4
    5

    Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.

    Published in:
    Journal of Medical Virology, 2013, v. 85, n. 1, p. 8, doi. 10.1002/jmv.23404
    By:
    • Ghosn, Jade;
    • Slama, Laurence;
    • Chermak, Aziza;
    • Houssaini, Allal;
    • Lambert‐Niclot, Sidonie;
    • Schneider, Luminita;
    • Fourn, Erwan;
    • Duvivier, Claudine;
    • Simon, Anne;
    • Courbon, Eve;
    • Murphy, Robert;
    • Flandre, Philippe;
    • Peytavin, Gilles;
    • Katlama, Christine
    Publication type:
    Article
    6

    Effect of antiretroviral drugs on the quality of semen.

    Published in:
    Journal of Medical Virology, 2011, v. 83, n. 8, p. 1391, doi. 10.1002/jmv.22119
    By:
    • Lambert-Niclot, Sidonie;
    • Poirot, Catherine;
    • Tubiana, Roland;
    • Houssaini, Allal;
    • Soulié, Cathia;
    • Dominguez, Stéphanie;
    • Schubert, Benoit;
    • Prades, Marie;
    • Bonmarchand, Manuela;
    • Calvez, Vincent;
    • Flandre, Philippe;
    • Peytavin, Gilles;
    • Marcelin, Anne-Geneviève
    Publication type:
    Article
    7
    8

    Virological and pharmacological factors associated with virological response to salvage therapy after an 8‐week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).

    Published in:
    Journal of Medical Virology, 2005, v. 77, n. 3, p. 345
    By:
    • Constance Delaugerre;
    • Gilles Peytavin;
    • Stephanie Dominguez;
    • Anne‐Genevieve Marcelin;
    • Claudine Duvivier;
    • Karine Gourlain;
    • Bahia Amellal;
    • Mayeule Legrand;
    • François Raffi;
    • Dominique Costagliola;
    • Christine Katlama;
    • Vincent Calvez
    Publication type:
    Article
    9

    Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patientsThis work was presented during the 2nd IAS Conference on HIV Pathogenesis and Treatment. 13–16 July 2003, Paris, France (abstract 165).

    Published in:
    Journal of Medical Virology, 2004, v. 74, n. 1, p. 16
    By:
    • Anne‐Geneviève Marcelin;
    • Dissou Affolabi;
    • Claire Lamotte;
    • Hocine Ait Mohand;
    • Constance Delaugerre;
    • Marc Wirden;
    • Delphine Voujon;
    • Philippe Bossi;
    • Nadine Ktorza;
    • François Bricaire;
    • Dominique Costagliola;
    • Christine Katlama;
    • Gilles Peytavin;
    • Vincent Calvez
    Publication type:
    Article
    10

    Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV.

    Published in:
    Journal of Personalized Medicine, 2023, v. 13, n. 4, p. 583, doi. 10.3390/jpm13040583
    By:
    • Sellem, Baptiste;
    • Abdi, Basma;
    • Lê, Minh;
    • Tubiana, Roland;
    • Valantin, Marc-Antoine;
    • Seang, Sophie;
    • Schneider, Luminita;
    • Fayçal, Antoine;
    • Peytavin, Gilles;
    • Soulié, Cathia;
    • Marcelin, Anne-Geneviève;
    • Katlama, Christine;
    • Pourcher, Valérie;
    • Palich, Romain
    Publication type:
    Article
    11
    12
    13
    14

    Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results.

    Published in:
    Journal of Antimicrobial Chemotherapy (JAC), 2024, v. 79, n. 11, p. 2932, doi. 10.1093/jac/dkae308
    By:
    • Serris, Alexandra;
    • Ferre, Valentine Marie;
    • Hingrat, Quentin Le;
    • Bachelard, Antoine;
    • Charpentier, Charlotte;
    • Exarchopoulos, Marina;
    • Damond, Florence;
    • Phung, Bao-Chau;
    • Landman, Roland;
    • Yazdanpanah, Yazdan;
    • Descamps, Diane;
    • Joly, Véronique;
    • Peytavin, Gilles;
    • Ghosn, Jade
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21
    22
    23

    "Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study.

    Published in:
    PLoS ONE, 2019, v. 14, n. 4, p. 1, doi. 10.1371/journal.pone.0216010
    By:
    • Gantner, Pierre;
    • Sylla, Babacar;
    • Morand-Joubert, Laurence;
    • Frange, Pierre;
    • Lacombe, Karine;
    • Khuong, Marie-Aude;
    • Duvivier, Claudine;
    • Launay, Odile;
    • Karmochkine, Marina;
    • Arvieux, Cédric;
    • Ménard, Amélie;
    • Piroth, Lionel;
    • Canestri, Ana;
    • Trias, Dominique;
    • Peytavin, Gilles;
    • Landman, Roland;
    • Ghosn, Jade;
    • null, null
    Publication type:
    Article
    24
    25
    26
    27
    28
    29
    30
    31
    32

    Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir + lamivudine simplification in the ANRS 167 LAMIDOL trial.

    Published in:
    Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 12, p. 2995, doi. 10.1093/jac/dkad344
    By:
    • Mazouz, Fella;
    • Bertine, Mélanie;
    • Coppée, Romain;
    • Storto, Alexandre;
    • Katlama, Christine;
    • Landman, Roland;
    • Cabié, André;
    • Peytavin, Gilles;
    • Raffi, François;
    • Yazdanpanah, Yazdan;
    • Descamps, Diane;
    • Joly, Véronique;
    • Ghosn, Jade;
    • Charpentier, Charlotte;
    • Group, the LAMIDOL Study
    Publication type:
    Article
    33

    HIV-1 infection in South Kivu (Democratic Republic of Congo): high genotypic resistance to antiretrovirals.

    Published in:
    Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 7, p. 1732, doi. 10.1093/jac/dkad163
    By:
    • Duhant, Alexandra;
    • Kusinza, Byabene;
    • Tantet, Claire;
    • Bisimwa, Basimane;
    • Gare, Mathilde;
    • Masemo, Bihehe;
    • Alloui, Chakib;
    • Ntakwinjan, Mukanire;
    • Mechai, Frédéric;
    • Le, Minh Patrick;
    • Gerber, Athenaïs;
    • Muhigirwa, Balthazar;
    • Peytavin, Gilles;
    • Gordien, Emmanuel;
    • Brichler, Ségolène;
    • Mukwege, Mukengere;
    • Gal, Frédéric Le
    Publication type:
    Article
    34

    Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study.

    Published in:
    Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 7, p. 1711, doi. 10.1093/jac/dkad161
    By:
    • Mandelbrot, Laurent;
    • Tubiana, Roland;
    • Frange, Pierre;
    • Peytavin, Gilles;
    • Chenadec, Jerome Le;
    • Canestri, Ana;
    • Morlat, Philippe;
    • Brunet-Cartier, Cécile;
    • Sibiude, Jeanne;
    • Peretti, Delphine;
    • Chambrin, Véronique;
    • Chabrol, Amélie;
    • Bui, Eida;
    • Simon-Toulza, Caroline;
    • Marchand, Lucie;
    • Paul, Christelle;
    • Delmas, Sandrine;
    • Avettand-Fenoel, Véronique;
    • Warszawski, Josiane;
    • group, the Monogest study
    Publication type:
    Article
    35

    Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study—IMEA 055.

    Published in:
    Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 3, p. 769, doi. 10.1093/jac/dkad008
    By:
    • Bachelard, Antoine;
    • Isernia, Valentina;
    • Charpentier, Charlotte;
    • Benalycherif, Aida;
    • Mora, Marion;
    • Donadille, Cécile;
    • Duvivier, Claudine;
    • Lacombe, Karine;
    • Mouhebb, Mayssam El;
    • Spire, Bruno;
    • Landman, Roland;
    • Descamps, Diane;
    • Peytavin, Gilles;
    • Assoumou, Lambert;
    • Ghosn, Jade;
    • group, FAST study
    Publication type:
    Article
    36

    Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.

    Published in:
    Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 3, p. 853, doi. 10.1093/jac/dkad009
    By:
    • Benaboud, Sihem;
    • Solas, Caroline;
    • Bouchet, Stephane;
    • Gregoire, Matthieu;
    • Lemaitre, Florian;
    • Venisse, Nicolas;
    • Lê, Minh Patrick;
    • Muret, Patrice;
    • Parant, Francois;
    • Neant, Nadege;
    • Boujafaar, Sana;
    • Lagoutte-Renosi, Jennifer;
    • Garraffo, Rodolphe;
    • Peytavin, Gilles
    Publication type:
    Article
    37

    HIV stigma limits the effectiveness of PMTCT in Guinea: the ANRS 12344-DIAVINA study.

    Published in:
    Journal of Antimicrobial Chemotherapy (JAC), 2022, v. 77, n. 11, p. 3093, doi. 10.1093/jac/dkac287
    By:
    • Breton, Guillaume;
    • Diallo, Oumou Hawa;
    • Cissé, Mohamed;
    • Diallo, Néné Aissatou;
    • Soumaoro, Sény Agnès;
    • Camara, Yalikhatou;
    • Montoyo, Alice;
    • Rouzioux, Christine;
    • Koita, Youssouf;
    • Peytavin, Gilles;
    • Tubiana, Roland;
    • Frange, Pierre;
    • group, the ANRS 12344-DIAVINA study;
    • ANRS 12344-DIAVINA study group
    Publication type:
    Article
    38

    Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.

    Published in:
    2022
    By:
    • Lingas, Guillaume;
    • Néant, Nadège;
    • Gaymard, Alexandre;
    • Belhadi, Drifa;
    • Peytavin, Gilles;
    • Hites, Maya;
    • Staub, Thérèse;
    • Greil, Richard;
    • Paiva, Jose-Artur;
    • Poissy, Julien;
    • Peiffer-Smadja, Nathan;
    • Costagliola, Dominique;
    • Yazdanpanah, Yazdan;
    • Wallet, Florent;
    • Gagneux-Brunon, Amandine;
    • Mentré, France;
    • Ader, Florence;
    • Burdet, Charles;
    • Guedj, Jérémie;
    • Bouscambert-Duchamp, Maude
    Publication type:
    Journal Article
    39
    40
    41
    42
    43
    44

    Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.

    Published in:
    2021
    By:
    • Palich, Romain;
    • Allavena, Clotilde;
    • Peytavin, Gilles;
    • Soulie, Cathia;
    • Tubiana, Roland;
    • Weiss, Laurence;
    • Ferrer, Ana Montoya;
    • Duvivier, Claudine;
    • Bouchaud, Olivier;
    • Bottero, Julie;
    • Durand, Aurore;
    • Lê, Minh-Patrick;
    • Marcelin, Anne-Geneviève;
    • Dudoit, Yasmine;
    • Assoumou, Lambert;
    • Katlama, Christine;
    • group, the ETRAL QD study;
    • Montoya Ferrer, Ana;
    • ETRAL QD study group
    Publication type:
    journal article
    45
    46

    Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response.

    Published in:
    2020
    By:
    • Katlama, Christine;
    • Assoumou, Lambert;
    • Valantin, Marc-Antoine;
    • Soulié, Cathia;
    • Martinez, Esteban;
    • Béniguel, Lydie;
    • Bouchaud, Olivier;
    • Raffi, François;
    • Molina, Jean-Michel;
    • Fellahi, Soraya;
    • Peytavin, Gilles;
    • Marcelin, Anne-Geneviève;
    • Kolta, Sami;
    • Capeau, Jacqueline;
    • Gibowski, Severine;
    • Cardon, Fanny;
    • Reynes, Jacques;
    • Costagliola, Dominique
    Publication type:
    Letter
    47
    48
    49
    50